ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2578

RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE

Gourav Choudhary1, Nick Huang2, Thomas Winans3, Ryan Kelly4, Sarah Blair3, Miguel Beckford3 and Andras Perl2, 1Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, 2Medicine, SUNY Upstate Medical University, Syracuse, NY, 3SUNY Upstate Medical University, Syracuse, NY, 4SUNY, Syracuse, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: ANA, SLE and glomerulonephritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systematic lupus erythematosus (SLE) is a multisystem chronic inflammatory disease characterized by circulating antinuclear autoantibodies and dysfunction of B cells, T cells, and dendritic cells. Polymorphism of the HRES-1/RAB4 genomic locus has been associated with disease manifestations, such as nephritis, in SLE patients (Arthritis Rheum. 58:532-520), and its Rab4A gene product is overexpressed in T cells of SLE patients and in mice prior to disease onset and, remarkably, inhibition of Rab geranylgeranyl transferase prevented antinuclear antibody (ANA) production and nephritis in lupus-prone mice (Ann. Rheum. Dis. 73:1887-1897). To determine the role of Rab4a in lupus pathogenesis, its impact on ANA production and nephritis was investigated in Rab4A-KOCD4Cre (Rab4AKO) mice lacking expression of Rab4A in T cells relative to wild-type (WT) and floxed Rab4AQ72L knock-in (Rab4AQ72L) controls.

Methods: Four WT, three Rab4AQ72L and four Rab4AKO female mice matched for age were injected intraperitoneally with 0.5 ml per 20 g of body weight of pristane. 14 days after injection, ANA levels were measured in sera by ELISA and immunoglobulin G (IgG) and M (IgM) and complement 3 (C3) deposition as well as infiltration by CD11b+ macrophages, CD11c+ dendritic cells, CD138+ plasma cells, and CD3+ T cells were assessed by immunofluorescence using confocal microscopy. Statistical analyses were performed by t-test; two-tailed p<0.05 was considered significant.

Results: ANA levels were increased in Rab4AKO relative to Rab4AQ72L controls. Deposition of IgG and IgM was increased 2-fold, and C3 deposition was increased 4-fold in glomeruli of Rab4AKO relative to WT and Rab4AQ72L controls. Further, T cells (12-fold), plasma cells (2-fold), and macrophages (7-fold), but not dendritic cels, were accumulated in glomeruli and tubular interstitium of Rab4AKO mice relative to WT and Rab4AQ72L controls.

Conclusion: Based on these results, Rab4A protects against ANA production and nephritis in the pristane-induced model of SLE.


Disclosure: G. Choudhary, None; N. Huang, None; T. Winans, None; R. Kelly, None; S. Blair, None; M. Beckford, None; A. Perl, None.

To cite this abstract in AMA style:

Choudhary G, Huang N, Winans T, Kelly R, Blair S, Beckford M, Perl A. RAB4A Protects from Antinuclear Antibody Production and Nephritis in the Pristane-Induced Model of SLE [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/rab4a-protects-from-antinuclear-antibody-production-and-nephritis-in-the-pristane-induced-model-of-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rab4a-protects-from-antinuclear-antibody-production-and-nephritis-in-the-pristane-induced-model-of-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology